Concepedia

S. Zildjian

SZ

Statistics

Publications

12

Citations

524

H-Index

11

Active since

2007

Affiliations

ImmunoGen (United States)(Current)

Dana-Farber Cancer Institute

University of California, San Francisco

Vall d'Hebron Institute of Oncology

Vall d'Hebron Hospital Universitari

S. Zildjian is an author at ImmunoGen (United States) specializing in cancer therapeutics, oncology, and radiation oncology.

Top concepts

Publications per year

2007–2022

12

Publications

12

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Ana Oaknin, Lucy Gilbert, Anna V. Tinker et al. · Journal for ImmunoTherapy of Cancer · 2022 · 300 citations · Full text

Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis

Asher Chanan‐Khan, Jeffrey L. Wolf, Juan Garcia et al. · Blood · 2010 · 38 citations

Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).

J. G. Berdeja, Sikander Ailawadhi, Steven Weitman et al. · Journal of Clinical Oncology · 2011 · 36 citations

, , +17

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan‐Khan, Jeffrey L. Wolf, Mecide Gharibo et al. · Blood · 2009 · 23 citations

Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma

John McCann, Frank V. Fossella, Miguel A. Villalona‐Calero et al. · Journal of Clinical Oncology · 2007 · 21 citations

, , +22

1–5 of 12